PEPTIDES for Veterans Act
- Sponsor
- Rep. Mace, Nancy [R-SC-1]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Sep 8, 2026
Bottom line
This bill initiates a multi-stage process for the Department of Veterans Affairs to explore and potentially integrate peptide-based therapies into veteran care, contingent on positive study findings.
What it actually does
This bill directs the Secretary of Veterans Affairs to first review existing regulations and definitions of peptides, then conduct a comprehensive study on the safety, efficacy, and potential therapeutic benefits of peptide-based therapies for veterans. If the study recommends it, the bill mandates a five-year pilot program to make these therapies available to veterans and assess their results.
Proponents argue
Supporters argue this bill is a proactive step to explore innovative medical treatments that could significantly improve the health and quality of life for veterans suffering from various service-connected conditions, chronic pain, and mental health issues. They contend that the VA should lead in evaluating cutting-edge therapies to ensure veterans have access to the best available care.
Opponents contend
Critics might argue that while exploring new therapies is important, the bill could potentially commit the VA to a lengthy and costly process for treatments that are not yet fully established or widely accepted in mainstream medicine. Concerns could also be raised about the potential for unproven therapies to be introduced without sufficient prior evidence, or the diversion of resources from existing, proven veteran care programs.
The bill is short and clearly written, making it easy for an informed reader to understand its provisions quickly.
Section 2
VA Review of Peptide Definitions and Guidance
This section requires the Secretary of Veterans Affairs to review current federal regulations and guidance concerning peptides, specifically focusing on how "peptide" is defined. The Secretary must then establish a new, appropriate definition for "peptide" and "peptide-based therapy" for the purposes of this Act, taking into account recent research developments. A report summarizing this review and the new definitions must be submitted to Congress within 180 days.
Supporters argue
Supporters argue that clear and updated definitions are essential for the VA to accurately assess and potentially integrate peptide-based therapies, ensuring consistency and scientific rigor in any future studies or programs.
Critics contend
No specific opposition is typically raised against a provision focused on defining terms, as it's a foundational step for any new policy. However, some might argue that the VA's definition could be too broad or too narrow, potentially hindering or prematurely limiting future research.
Tradeoffs
The tension lies in balancing a broad definition that allows for future innovation with a precise definition that ensures safety and regulatory clarity.
Section 3(a)
Study on Safety, Efficacy, and Benefits of Peptide-Based Therapies
This section mandates the VA to conduct a study on peptide-based therapies for veterans receiving VA care. The study will assess the safety, efficacy, and potential therapeutic benefits, including applications for recovery, rehabilitation, chronic pain, mental health, and other service-connected conditions. It also requires a review of medical research, establishment of clinical protocols, and consideration of peptide safety. The study must be completed within 18 months, followed by a report to Congress with findings, recommendations, and a determination on whether these therapies should be made available.
Section 3(b)
Pilot Program for Veterans' Access to Peptide-Based Therapies
This section mandates a pilot program to make peptide-based therapies available to veterans, but only if the VA Secretary's study (from Section 3(a)) determines that these therapies should be provided. Participation in the pilot program is voluntary for veterans, and the Secretary can set geographic, clinical, or other limitations. The program will run for five years, after which a report detailing its effectiveness, guidance for broader implementation, and challenges encountered must be submitted to Congress.